Alexander G J
Liver Unit, King's College School of Medicine and Dentistry, Denmark Hill, London, UK.
Chemioterapia. 1988 Dec;7 Suppl 3:9-11.
alpha-Interferon and beta-interferon have been used therapeutically in chronic hepatitis B virus (HBV) infection for more than a decade. It is now clear that alpha-interferons are an effective therapy for a proportion of chronic HBV carriers. A course of at least three, and possibly as long as 4 months is required at a dose of 5-10 MU three times a week. Those responding to therapy usually develop a marked hepatitis in the second and third months of therapy, which precedes permanent loss of markers of viral replication. In a proportion of patients, not only are HBe antigen and HBV DNA cleared from serum, but HBsAg may also be cleared, albeit over a longer time course; anti-HBs develops in a few of these patients. Although close to being an established form of therapy for chronic HBV infection, the responsive subgroups remain to be defined. Studies over the next few years will be directed at identifying those groups responsive, or not responsive, to alpha-interferons and thereafter seeking other antiviral agents that could be used in combination with alpha-interferon to augment the response rate.
α干扰素和β干扰素用于慢性乙型肝炎病毒（HBV）感染的治疗已有十多年。现在很清楚，α干扰素对一部分慢性HBV携带者是一种有效的治疗方法。治疗疗程至少需要三个月，可能长达四个月，剂量为每周三次，每次5-10百万单位。对治疗有反应的患者通常在治疗的第二和第三个月会出现明显的肝炎，这先于病毒复制标志物的永久性消失。在一部分患者中，不仅血清中的HBe抗原和HBV DNA被清除，HBsAg也可能被清除，尽管需要更长的时间过程；其中一些患者会产生抗-HBs。尽管α干扰素几乎已成为慢性HBV感染的一种既定治疗形式，但仍有待确定有反应的亚组。未来几年的研究将致力于确定那些对α干扰素有反应或无反应的群体，然后寻找其他可与α干扰素联合使用以提高反应率的抗病毒药物。
